Plasma protease C1-inhibitor treatment is a plasma-derived therapeutic used for the treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder characterized by episodes of severe swelling. Plasma protease C1-inhibitor treatment offers advantages such as reduced severity and frequency of HAE attacks.
The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: High unmet medical needs present a major market opportunity. Currently available treatment options suffer from certain limitations such as requirement of frequent dosing or intravenous administration. This leaves behind a sizable unmet need for easily administrable therapies with improved efficacy. Development of novel oral drugs or long acting therapies can help address this unmet need more effectively. This in turn is expected to boost the overall market growth during the forecast period. Porter's Analysis Threat of new entrants: The plasma protease C1-inhibitor treatment market requires huge R&D investment and regulatory approvals which makes it difficult for new players to enter. Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment options are limited and life saving. Bargaining power of suppliers: A few biotech companies dominate the supply chain resulting in higher bargaining power. Threat of new substitutes: Currently there are no effective substitutes available limiting threat from substitutes. Competitive rivalry: Major players compete on proprietary technologies and expanding indications resulting in high competitive rivalry. SWOT Analysis Strength: Established production facilities and strong R&D capabilities of major players. Demand is expected to rise with increasing prevalence of hereditary angioedema. Weakness: High treatment cost limiting accessibility. Requirement of patient monitoring and recurrent administrations. Opportunity: Scope for development of subcutaneous and extended half-life products. Approvals in new geographic regions. Threats: Price control regulations and strict biosimilar approval pathways. Supply chain disruptions and recalls. Key Takeaways The Global Plasma Protease C1-Inhibitor Treatment Market Growth is expected to witness high during the forecast period. The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030. North America dominates currently due to rapid adoption and high healthcare spending. Regional markets in Asia Pacific and Latin America are expected to grow at a higher pace due to rising awareness, diagnosis and economic growth. Key players operating in the plasma protease C1-inhibitor treatment market are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring dominates with leading intravenous products. Takeda and Ionis are developing subcutaneous options. Pharming and KalVista are exploring extended half-life versions to overcome limitations of frequent dosing. Explore more information on this topic, Please visit- https://www.dailyprbulletin.com/plasma-protease-c1-inhibitor-treatment-market-share-size-and-growth-share-trends-analysis-demand-forecast/
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |